TARRYTOWN, N.Y., Aug. 2, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) will host a conference call and webcast to discuss its financial results for the second quarter 2013 on Friday, August 9, at 8:30 a.m. ET.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 27841136. A live webcast will be available in the Media Center of the newly redesigned Progenics website, www.progenics.com . A replay will be available on the website for two weeks.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics' first-in-class PSMA targeted technology platform includes an antibody drug conjugate therapeutic and a small molecule targeted imaging agent, both in Phase 2 clinical trials. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra TM, an ultra-orphan radiotherapy candidate also in phase 2 under an SPA. Progenics' first commercial product, Relistor ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. Ono Pharmaceutical Co. is developing Relistor in Japan. For additional information, please visit www.progenics.com .(PGNX-G)
CONTACT: Kathleen Fredriksen Corporate Development (914) 789-2871 firstname.lastname@example.org